Table I.
Characteristics of the overall cohort of patients with clinical stage I-III NSCLC undergoing lobectomy after neoadjuvant chemotherapy vs neoadjuvant immunotherapy.
| Characteristics | Chemotherapy (n=4011) | Immunotherapy (n=218) | p-value |
|---|---|---|---|
| Age at diagnosis, median (IQR) | 64.0 (57.0, 70.0) | 65.0 (57.0, 72.0) | 0.13 |
| Sex, no. (%, female) | 2037 (50.8%) | 119 (54.6%) | 0.27 |
| Race, no. (%) | |||
| White | 3401 (84.8%) | 190 (87.2%) | 0.71 |
| Black | 376 (9.4%) | 17 (7.8%) | |
| Native American | 13 (0.3%) | 0 (0.0%) | |
| Asian | 148 (3.7%) | 6 (2.8%) | |
| Unknown | 73 (1.8%) | 5 (2.3%) | |
| Charlson-Deyo Comorbidity Score, no. (%) | |||
| 0 | 2416 (60.2%) | 122 (56.0%) | 0.29 |
| 1 | 1135 (28.3%) | 67 (30.7%) | |
| 2 | 338 (8.4%) | 18 (8.3%) | |
| 3+ | 122 (3.0%) | 11 (5.0%) | |
| Clinical stage, no. (%) | |||
| Ia | 106 (2.6%) | 11 (5.0%) | <0.001 |
| Ib | 155 (3.9%) | 17 (7.8%) | |
| IIa | 105 (2.6%) | 12 (5.5%) | |
| IIb | 682 (17.0%) | 56 (25.7%) | |
| IIIa | 2087 (52.0%) | 91 (41.7%) | |
| IIIb | 824 (20.5%) | 29 (13.3%) | |
| IIIc | 52 (1.3%) | 2 (0.9%) | |
| Tumor size (mm; median, IQR) | 40.0 (26.0, 59.0) | 41.0 (25.0, 60.0) | 0.75 |
| Tumor location, no. (%) | |||
| Main bronchus | 25 (0.6%) | 2 (0.9%) | 0.09 |
| Right upper lobe | 1656 (41.3%) | 79 (36.2%) | |
| Right middle lobe | 163 (4.1%) | 5 (2.3%) | |
| Right lower lobe | 550 (13.7%) | 44 (20.2%) | |
| Left upper lobe | 1042 (26.0%) | 53 (24.3%) | |
| Left lower lobe | 440 (11.0%) | 30 (13.8%) | |
| Unknown/other | 160 (3.9%) | 7 (3.2%) | |
| Histology, no. (%) | |||
| Adenocarcinoma | 1996 (49.8%) | 119 (54.6%) | 0.18 |
| Squamous cell carcinoma | 1285 (32.0%) | 70 (32.1%) | |
| Other/Unknown | 730 (18.2%) | 29 (13.4%) | |
| Grade differentiation, no. (%) | |||
| Well differentiated | 135 (3.4%) | 11 (5.0%) | 0.002 |
| Moderately differentiated | 1012 (25.2%) | 43 (19.7%) | |
| Poorly differentiated | 1541 (38.4%) | 69 (31.7%) | |
| Undifferentiated | 41 (1.0%) | 0 (0.0) | |
| Cell type not determined | 1282 (32.0%) | 95 (43.6%) | |
| Primary payor at diagnosis, no. (%) | |||
| Not insured | 82 (2.0%) | 1 (0.5%) | 0.15 |
| Private insurance | 1673 (41.7%) | 96 (44.0%) | |
| Medicaid | 288 (7.2%) | 17 (7.8%) | |
| Medicare | 1846 (46.0%) | 98 (45.0%) | |
| Other government | 60 (1.5%) | 0 (0.0%) | |
| Unknown | 62 (1.5%) | 6 (2.8%) | |
| Facility type, no. (%) | |||
| Community cancer program | 88 (2.2%) | 1 (0.5%) | <0.001 |
| Comprehensive community cancer program | 1156 (28.8%) | 32 (14.7%) | |
| Academic research program | 1944 (48.5%) | 167 (76.6%) | |
| Integrated network cancer program | 784 (19.5%) | 15 (6.9%) | |
| Unknown | 39 (1.0%) | 3 (1.4%) | |
| Distance from hospital (median, IQR) | 13.6 (5.9, 34.0) | 18.8 (8.4, 56.7) | <0.001 |
| Median income (census tract), no. (%) | |||
| <$40,227 | 610 (15.2%) | 25 (11.5%) | 0.053 |
| $40,227-$50,353 | 752 (18.7%) | 39 (17.9%) | |
| $50,354-$63,332 | 815 (20.3%) | 37 (17.0%) | |
| ≥$63,333 | 1344 (33.5%) | 92 (42.2%) | |
| Unknown | 490 (12.2%) | 25 (11.5%) | |
| Median education (census tract), no. (%) | |||
| 17.6% without a high school degree | 683 (17.0%) | 37 (17.0%) | 0.38 |
| 10.9–17.5% without a high school degree | 943 (23.5%) | 54 (24.8%) | |
| 6.3–10.8% without a high school degree | 1092 (27.2%) | 50 (22.9%) | |
| <6.3% without a high school degree | 816 (20.3%) | 53 (24.3%) | |
| Unknown | 477 (11.9%) | 24 (11.0%) | |
| Year of diagnosis, median (IQR) | 2014.0 (2012.0, 2016.0) | 2017.0 (2017.0, 2018.0) | <0.001 |